Internet Archive Scholar

Bromfenac in ophthalmic practice
Возможности применения бромфенака в офтальмологической практике

M.L. Maksimov, Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuous Professional Education, Kazan, Russian Federation, A.A. Zvegintseva, I.D. Kanner, N.M. Lapkin, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation, Pirogov Russian National Research Medical University, Moscow, Russian Federation, Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuous Professional Education, Kazan, Russian Federation, Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation, Lomonosov Moscow State University, Moscow, Russian Federation, Yaroslavl State Medical University, Yaroslavl, Russian Federation
2021 Clinical ophthalmology  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (1.4 MB)
https://web.archive.org/web/20220318013506/https://clinopht.com/upload/iblock/5ef/5ef539fda3aceb492f42fac37acc1f08.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

Non-steroidal anti-inflammatory drugs (NSAIDs) are essential for the treatment of ocular disorders. While corticosteroids are the gold standard for inflammatory ocular diseases, comparative studies on the efficacy of NSAIDs and corticosteroids have demonstrated no significant differences in outcomes. Given the chemical structure of NSAIDs, it should be noted that salicylates, phenamates, and pyrazoline derivatives are either toxic or unstable. Solubilizers and preservatives also account for
more » ... city. Bromfenac-based medications are characterized by high safety and contain minimum benzalkonium chloride. This paper reviews advantages of a modern topical NSAID, bromfenac, for ocular use. This medication is more effective than diclofenac (by 3.7 times), amfenac (by 6.5 times), and ketorolac (by 18 times) in terms of inhibiting COG-2. Furthermore, the regimen of use (twice daily), no discomfort, and excellent safety profile with minimal adverse effects improve treatment adherence. In addition, Bromfenac, a topical antiinflammatory agent, improves patients' satisfaction with surgical outcomes since patients achieve maximum possible visual acuity as early as possible. Keywords: non-steroidal anti-inflammatory drugs, NSAIDs, bromfenac, arachidonic acid, inflammation, corticosteroids, eye surgery, cataract, cystoid macular edema. For citation: Maksimov M.L., Zvegintseva A.A., Kanner I.D., Lapkin N.M. Bromfenac in ophthalmic practice. Russian Journal of Clinical Ophthalmology. 2021;21(4):241–248 (in Russ.). DOI: 10.32364/2311-7729-2021-21-4-241-248.
doi:10.32364/2311-7729-2021-21-4-241-248 fatcat:xftvtt6c5zdzfdllha2pbqosxi
DOAJ
Citation

M.L. Maksimov, Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuous Professional Education, Kazan, Russian Federation, A.A. Zvegintseva, I.D. Kanner, N.M. Lapkin, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation, Pirogov Russian National Research Medical University, Moscow, Russian Federation, Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuous Professional Education, Kazan, Russian Federation, Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russian Federation, Lomonosov Moscow State University, Moscow, Russian Federation, Yaroslavl State Medical University, Yaroslavl, Russian Federation. "Bromfenac in ophthalmic practice." Clinical ophthalmology 21.4 (2021) 241-248